Last reviewed · How we verify

Bricanyl/Iprovent

University of Monastir · Phase 3 active Small molecule

Bricanyl (terbutaline) is a beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.

Bricanyl (terbutaline) is a beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Asthma, Chronic obstructive pulmonary disease (COPD), Reversible airway obstruction.

At a glance

Generic nameBricanyl/Iprovent
SponsorUniversity of Monastir
Drug classBeta-2 adrenergic agonist (Bricanyl); Anticholinergic bronchodilator (Iprovent)
TargetBeta-2 adrenergic receptor (Bricanyl); Muscarinic acetylcholine receptor (Iprovent)
ModalitySmall molecule
Therapeutic areaRespiratory/Pulmonology
PhasePhase 3

Mechanism of action

Terbutaline binds to and activates beta-2 adrenergic receptors on bronchial smooth muscle, triggering a cascade that increases intracellular cAMP and leads to smooth muscle relaxation and airway dilation. This mechanism provides rapid relief of bronchoconstriction in obstructive airway diseases. Iprovent (ipratropium) is an anticholinergic agent that blocks muscarinic receptors to prevent acetylcholine-induced bronchoconstriction, often used in combination with beta-2 agonists for enhanced bronchodilation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: